97 related articles for article (PubMed ID: 29464593)
1. Improving Properties of Albendazole Desmotropes by Supramolecular Systems with Maltodextrin and Glutamic Acid.
Bongioanni A; Araújo BS; de Oliveira YS; Longhi MR; Ayala A; Garnero C
AAPS PharmSciTech; 2018 Apr; 19(3):1468-1476. PubMed ID: 29464593
[TBL] [Abstract][Full Text] [Related]
2. Toward novel antiparasitic formulations: Complexes of Albendazole desmotropes and β-cyclodextrin.
Chattah AK; Pfund LY; Zoppi A; Longhi MR; Garnero C
Carbohydr Polym; 2017 May; 164():379-385. PubMed ID: 28325339
[TBL] [Abstract][Full Text] [Related]
3. Salt screening and characterization for poorly soluble, weak basic compounds: case study albendazole.
Paulekuhn GS; Dressman JB; Saal C
Pharmazie; 2013 Jul; 68(7):555-64. PubMed ID: 23923637
[TBL] [Abstract][Full Text] [Related]
4. Supramolecular complexes of maltodextrin and furosemide polymorphs: a new approach for delivery systems.
Garnero C; Chattah AK; Longhi M
Carbohydr Polym; 2013 Apr; 94(1):292-300. PubMed ID: 23544541
[TBL] [Abstract][Full Text] [Related]
5. Preparation, physicochemical characterization and drug release studies of albendazole solid dispersions.
Mallick S; Sahoo A; Mitra SS
Boll Chim Farm; 2003 May; 142(4):180-6. PubMed ID: 12918228
[TBL] [Abstract][Full Text] [Related]
6. Investigating albendazole desmotropes by solid-state NMR spectroscopy.
Chattah AK; Zhang R; Mroue KH; Pfund LY; Longhi MR; Ramamoorthy A; Garnero C
Mol Pharm; 2015 Mar; 12(3):731-41. PubMed ID: 25584993
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of a new cyclodextrin derivative with improved properties to design oral dosage forms.
García A; Priotti J; Codina AV; Vasconi MD; Quiroga AD; Hinrichsen LI; Leonardi D; Lamas MC
Drug Deliv Transl Res; 2019 Feb; 9(1):273-283. PubMed ID: 30264285
[TBL] [Abstract][Full Text] [Related]
8. Improved albendazole dissolution rate in pluronic 188 solid dispersions.
Castro SG; Bruni SS; Lanusse CE; Allemandi DA; Palma SD
AAPS PharmSciTech; 2010 Dec; 11(4):1518-25. PubMed ID: 20945166
[TBL] [Abstract][Full Text] [Related]
9. Promising applications in drug delivery systems of a novel β-cyclodextrin derivative obtained by green synthesis.
García A; Leonardi D; Lamas MC
Bioorg Med Chem Lett; 2016 Jan; 26(2):602-608. PubMed ID: 26642766
[TBL] [Abstract][Full Text] [Related]
10. Chitosan microparticles: influence of the gelation process on the release profile and oral bioavailability of albendazole, a class II compound.
Piccirilli GN; García A; Leonardi D; Mamprin ME; Bolmaro RE; Salomón CJ; Lamas MC
Drug Dev Ind Pharm; 2014 Nov; 40(11):1476-82. PubMed ID: 23971494
[TBL] [Abstract][Full Text] [Related]
11. Improving furosemide polymorphs properties through supramolecular complexes of β-cyclodextrin.
Garnero C; Chattah AK; Longhi M
J Pharm Biomed Anal; 2014 Jul; 95():139-45. PubMed ID: 24667568
[TBL] [Abstract][Full Text] [Related]
12. Complexation and solubility behavior of albendazole with some cyclodextrins.
Díaz D; Bernad Bernad MJ; Gracia Mora J; Escobar Llanos CM
Pharm Dev Technol; 1998 Aug; 3(3):395-403. PubMed ID: 9742560
[TBL] [Abstract][Full Text] [Related]
13. Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide.
Jung H; Medina L; García L; Fuentes I; Moreno-Esparza R
J Pharm Pharmacol; 1998 Jan; 50(1):43-8. PubMed ID: 9504433
[TBL] [Abstract][Full Text] [Related]
14. Novel albendazole formulations given during the intestinal phase of Trichinella spiralis infection reduce effectively parasitic muscle burden in mice.
García A; Barrera MG; Piccirilli G; Vasconi MD; Di Masso RJ; Leonardi D; Hinrichsen LI; Lamas MC
Parasitol Int; 2013 Dec; 62(6):568-70. PubMed ID: 23993995
[TBL] [Abstract][Full Text] [Related]
15. Albendazole Microcrystal Formulations Based on Chitosan and Cellulose Derivatives: Physicochemical Characterization and In Vitro Parasiticidal Activity in Trichinella spiralis Adult Worms.
Priotti J; Codina AV; Leonardi D; Vasconi MD; Hinrichsen LI; Lamas MC
AAPS PharmSciTech; 2017 May; 18(4):947-956. PubMed ID: 27882479
[TBL] [Abstract][Full Text] [Related]
16. Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process.
Kataoka M; Fukahori M; Ikemura A; Kubota A; Higashino H; Sakuma S; Yamashita S
Eur J Pharm Biopharm; 2016 Apr; 101():103-11. PubMed ID: 26873006
[TBL] [Abstract][Full Text] [Related]
17. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
18. Study on the dissolution improvement of albendazole using reconstitutable dry nanosuspension formulation.
Fülöp V; Jakab G; Bozó T; Tóth B; Endrésik D; Balogh E; Kellermayer M; Antal I
Eur J Pharm Sci; 2018 Oct; 123():70-78. PubMed ID: 30010031
[TBL] [Abstract][Full Text] [Related]
19. Enantiotropically related albendazole polymorphs.
Pranzo MB; Cruickshank D; Coruzzi M; Caira MR; Bettini R
J Pharm Sci; 2010 Sep; 99(9):3731-42. PubMed ID: 20112428
[TBL] [Abstract][Full Text] [Related]
20. Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation.
Yousaf AM; Kim DW; Oh YK; Yong CS; Kim JO; Choi HG
Int J Nanomedicine; 2015; 10():1819-30. PubMed ID: 25784807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
